Healthcare · Biotech & pharma
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Press release – No. 21 / 2026
Oct 19 · 05:00GlobeNewswire
2,246 press releases in English indexed under biotech & pharma.
Press release – No. 21 / 2026
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid.
Collaboration spans Copper-67 supply and radiopharmaceutical manufacturing from clinical development through commercialization. Partnership leverages NorthStar's vertically integrated campus, combining proprietary Copper-67 production technology, cGMP manufacturing, and commercial-scale infrastructure. BASEL, Switzerland
Quantum Application Forum, 3 November 2026, gives executives a practical view of where quantum can create commercial value Summary : Real-world quantum use cases: One-day forum on quantum applications for business and public sector priorities in financial services, healthcare, pharmaceuticals, materials science, energy an
SHANGHAI, Oct. 18, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv")...
In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its...
Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations Signatera ™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera's ESMO program AUSTIN, Texas, October 18, 2026 --( BUS
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO...
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for...
SAN DIEGO, Oct. 18, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026.